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flow during ex vivo renal perfusion in an 
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Sarah A. Hosgood*, Tom Moore, Theresa Kleverlaan, Tom Adams and Michael L. Nicholson
Abstract 
Background: Ex-vivo normothermic perfusion strategies are a promising new instrument in organ transplantation. 
The perfusion conditions are designed to be protective however the artificial environment can induce a local inflam-
matory response. The aim of this study was to determine the effect of incorporating a Cytosorb adsorber into an 
isolated kidney perfusion system.
Methods: Porcine kidneys were subjected to 22 h of cold ischaemia then reperfused for 6 h on an ex vivo reperfu-
sion circuit. Pairs of kidneys were randomised to either control (n = 5) or reperfusion with a Cytosorb adsorber (n = 5) 
integrated into the circuit. Tissue, blood and urine samples were taken for the measurement of inflammation and 
renal function.
Results: Baseline levels of cytokines (IL-6, TNFα, IL-8, IL-10, IL-1β, IL-1α) were similar between groups. Levels of IL-6 
and IL-8 in the perfusate significantly increased during reperfusion in the control group but not in the Cytosorb 
group (P = 0.023, 0.049). Levels of the other cytokines were numerically lower in the Cytosorb group; however, this 
did not reach statistical significance. The mean renal blood flow (RBF) was significantly higher in the Cytosorb group 
(162 ± 53 vs. 120 ± 35 mL/min/100 g; P = 0.022). Perfusate levels of prostaglandin E2 were significantly lower in the 
Cytosorb group (642 ± 762 vs. 3258 ± 980 pg/mL; P = 0.0001). Levels of prostacyclin were significantly lower in the 
Cytosorb group at 1, 3 and 6 h of reperfusion (P = 0.008, 0.003, 0.0002). Levels of thromboxane were also significantly 
lower in the Cytosorb group throughout reperfusion (P = 0.005). Haemoadsorption had no effect on creatinine clear-
ance (P = 0.109).
Conclusion: Haemoadsorption can reduce the inflammatory response and improve renal blood flow during 
perfusion. Nonetheless, in this model haemoadsorption had no influence on renal function and this may relate to 
the broad-spectrum action of the Cytosorb adsorber that also removes potentially important anti-inflammatory 
mediators.
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Background
The adoption of ex  vivo normothermic perfusion tech-
nologies in clinical transplantation offers significant 
advantages compared to hypothermic techniques [1–3]. 
Restoring function ex vivo upregulates protective mech-
anisms [4], replenishes cellular energy [5] and allows 
a functional assessment of an organ prior to transplan-
tation [6]. Although organs are perfused in a protective 
environment without leukocytes or complement, inflam-
matory processes are upregulated [4]. This is possibly due 
to the mechanical process of perfusion and direct contact 
of the perfusate with artificial surfaces. The consequences 
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of this heightened inflammatory response in this set-
ting are unknown. Although they appear not to have 
a detrimental effect on graft outcome, removing them 
during perfusion may be beneficial. Inflammatory media-
tors play an important role in exacerbating the sever-
ity of renal ischaemia reperfusion injury (IRI) [7]. IRI is 
a complicated multifactorial process causing damage 
to the vascular endothelial cells and tubular epithelium 
due to the production of reactive oxygen species (ROS), 
upregulation of pro-inflammatory cytokines, recruit-
ment of neutrophils, and complement and platelet activa-
tion [8–10]. In transplantation, periods of warm and cold 
ischaemia exacerbate IRI causing graft dysfunction and 
reducing graft survival [11, 12].
The removal of cytokines using haemoadsorption has 
been advocated in the management of severe inflamma-
tory-driven disease states such as sepsis [13] and severe 
systemic inflammatory response syndrome (SIRS) [14–
16]. Although haemoadsorption effectively reduces the 
concentration of circulating cytokines and improves sur-
vival, its effectiveness in other circumstances, such as dur-
ing cardiopulmonary bypass, remains inconclusive [17].
Locally within the kidney, circulating cells and tubular 
epithelial cells produce numerous cytokines. Pro-inflam-
matory cytokines such as IL-1β, IL-6, TNFα and IL-8 
are expressed in the early revascularisation phase after 
transplantation [18–20]. They orchestrate a network of 
interlinked responses causing tissue damage. The Cyto-
sorb adsorber is most effective for removing molecules in 
the 10–50 kDa range, which includes many anti- but also 
pro-inflammatory cytokines [21]. Therefore, the overall 
effect of the Cytosorb adsorber will depend on the bal-
ance between removal of beneficial and deleterious medi-
ators. The aim of this study was to examine the effect of 
cytokine haemoadsorption in an isolated kidney perfu-
sion system.
Methods
Kidney retrieval
Under Home Office ‘The Animals’ (Scientific Procedures) 
Act 1986 in the UK, five landrace cross pigs weighing 
61.6 ± 7.9 kg underwent a general anaesthesia and mid-
line laparotomy. Both renal pedicles were exposed and 
the kidneys dissected. A bolus injection of 25000  IU 
heparin was given 5 min before the renal artery and renal 
veins were ligated and the kidneys removed. One litre 
of blood was collected from the aorta into two citrate–
phosphate-dextrose-adenine blood bags before the ani-
mal was culled with an overdose of barbiturate.
Preservation
Immediately after retrieval the kidneys were flushed 
with 500  mL of ice-cold University of Wisconsin (UW) 
preservation solution at a hydrostatic pressure of 
100 mmHg. Kidneys were then placed in bags containing 
ice-cold UW solution, packed in ice and stored for 22 h.
Ex‑vivo perfusion system
After removal from cold storage the kidneys were 
weighed and prepared for reperfusion on the ex vivo per-
fusion circuit. The renal artery, vein and ureter were can-
nulated and the kidney was flushed with 200 mL of cold 
Ringer’s solution to remove the preservation solution.
Perfusion was carried out using an adapted paediatric 
cardiac bypass system (Medtronic, Bioconsole 560) as 
described previously [4, 5]. The ex  vivo perfusion sys-
tem was primed with 300  mL Ringer’s solution (Baxter 
Healthcare, Thetford UK), 2.5 g Mannitol (Baxter Health-
care), 12  mL sodium bicarbonate 8.4% (Fresenius Kabi, 
Runcorn, UK) and 3000  IU heparin (LEO Pharma A/S, 
Ballerup, Denmark). Whole blood (300  mL) was then 
added and recirculated to a temperature of 37.4  °C. The 
blood-based solution was oxygenated with a balance of 
95% oxygen/5%  CO2 at a flow rate of 0.1 L/min.
The blood-based solution was circulated continually 
through the kidney via the renal artery at a mean arte-
rial pressure of 85 mmHg and pump speed of 1500 RPM. 
A nutrient solution (Synthamin 17 10%, Baxter Health-
care) with 15 mL of sodium bicarbonate 8.4% and 100 IU 
of insulin added (Actrapid, Novo Nordisk, London, UK) 
was infused at a rate of 20  mL/h. Glucose 5% (Baxter 
Healthcare) was infused at a rate of 5 mL/h and Ringer’s 
solution was used to replace urine output (mL for mL).
Study design
A computerised sequence was generated and pairs of kid-
neys randomised to either control or Cytosorb adsorber 
(Cytosorb, LINC Medical Systems Ltd, Leicester, UK) 
(n = 5 kidneys per group).
The Cytosorb adsorber was flushed and primed with 
Ringer’s solution then added to the circuit by connect-
ing it to the line from the oxygenator allowing the blood 
to flow through the adsorber back into the venous res-
ervoir in parallel with the main flow to the renal artery 
(Fig. 1).
Outcome measures
The renal blood flow (RBF) was recorded every 5 min for 
the 30 min and thereafter every 30 min. Samples of per-
fusate (arterial and venous) were collected pre-perfusion 
then hourly. Urine samples were collected hourly.
Samples of perfusate and urine were sent to biochem-
istry for the measurement of urea and electrolytes. Sam-
ples of perfusate were also sent for haematology analysis.
Samples of venous perfusate and urine were centri-
fuged at 1600  rpm for 10  min at 4  °C. The supernatant 
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was collected and frozen in liquid nitrogen then stored at 
− 70 °C until analysed.
Samples of arterial and venous perfusate were col-
lected at 1, 3 and 6 h of reperfusion for blood gas analysis 
(OPTI-CCS). Oxygen consumption was calculated (arte-
rial  PaO2 – venous  PaO2 × RBF/weight of kidney).
RNA extraction and relative gene expression
Core biopsies were taken from each kidney (n  =  10) 
in situ (baseline) and after 6 h of perfusion. Biopsies were 
stored in RNA later solution (Invitrogen RNA later™ 
Soln.) for fixing. The tissue was lysed (Precellys Lysing 
Kit MK28-R) and RNA was extracted (Invitrogen Pure-
Link™ RNA Mini Kit & Invitrogen TURBO DNA-free™ 
Kit). The RNA was used to generate the cDNAs for each 
sample by reverse transcription (Applied Biosystems 
High Capacity cDNA Reverse Transcription Kit). Prim-
ers for ICAM-1, IL-1β, IL-6, IL-8, HMGB-1, TLR4 and 
RPL4 were designed using NCBI Primer Blast (Appendix: 
Table 2). Relative qPCR (Stratagene Mx3005P) was then 
performed using SYBR Green (Applied Biosystems Power 
 SYBR® Green PCR Master Mix) on baseline and 6  h 
perfusion samples for all kidneys and all genes. Cycling 
conditions are shown in Appendix: Table  3. Samples 
were assayed in triplicate and Ct values were averaged 
for each gene. The housekeeping gene (RPL4) Ct value 
was subtracted from the average Ct value of other genes 
within that sample (ΔCt). Since the kidneys were paired, 
the control ΔCt value was subtracted from the Cytosorb 
adsorber ΔCt value (ΔΔCt). The relative fold change for 
each gene between treatment and control was then cal-
culated using  2−ΔΔCt. The same analysis was performed 
comparing the relative expression difference within each 
kidney between baseline and 6 h.
Protein analysis
Perfusate levels of the following cytokines and inflammatory/
injury markers were measured by ELISA as per the manu-
facturer’s instructions; IL-1α, IL-1β, IL-6, IL-8, IL-10, TNFα 
(R&D Systems), CRP (R&D Systems Porcine C-Reactive 
Protein/CRP) and neutrophil gelatinase-associated lipoca-
lin (NGAL) (Elabscience Porcine NGAL ELISA). Perfusate 
levels of IL-1RA (Elabscience Porcine IL-1RA ELISA Kit) 
Prostaglandin  E2 Assay, prostacyclin (PG12) and thrombox-
ane B1 (R&D Systems), HMGB1 (Cusabio Pig High Mobil-
ity Group Protein B1), heme (BioVision Heme Colorimetric 
Assay Kit) and urinary levels of NGAL were also measured.
Statistics
Values are presented as mean ± standard deviation. Con-
tinuous variables such as RBF were plotted against time. 
Values were compared using a paired t test. P  ≤  0.050 
was considered statistically significant. Statistical analy-
sis was performed using Microsoft Excel and Graphpad 
Prism 7 (GraphPad Software Inc., La Jolla, CA, USA).
Results
The mean cold ischaemic times in the Cytosorb and con-
trol groups were 21.7 ±  0.3  h and 22.9 ±  0.3  h respec-
tively (P = 0.196).
Fig. 1 A schematic diagram of the perfusion circuit. The blood based perfusate circulates from the venous reservoir into the centrifugal pump. It 
is pumped into the membrane oxygenator at a set pump speed and mean arterial pressure were it is oxygenated and warmed to 37.4 °C before 
entering into the arterial arm of the circuit and into the kidney via the renal artery. The Cytosorb was attached to a line from the oxygenator then 
fed back into the venous reservoir allowing a collateral circulation of the perfusate without altering the renal blood flow
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Haemodynamics
The haematocrit (HCT) and platelet count were signifi-
cantly lower in the Cytosorb group at the start of perfu-
sion compared to the control (P  =  0.046, 0.008, 0.003, 
respectively; Table 1). At 6 h there was no significant dif-
ference in the HCT or Hb counts (P = 0.650, 0.626, 0.444, 
respectively; Table  1). However, the platelet count was 
significantly lower in the Cytosorb group (P  =  0.0003), 
falling by 50% compared with 40% in the control during 
perfusion.
Baseline levels of heme in the perfusate were simi-
lar between groups (P  =  0.785; Table  1). There was a 
numerical increase in the control group during perfu-
sion (P  =  0.356) and levels were numerically higher in 
the control group compared to the Cytosorb group at 6 h 
(P = 0.342; Table 1).
At the start of perfusion the mean RBF was similar 
between the groups (Fig.  2). In the control group dur-
ing the first 20  min of perfusion, the RBF fell and then 
remained stable before starting to increase after 3  h. In 
the Cytosorb group there was an increase in the RBF over 
the first 30 min of perfusion. The RBF then fell abruptly 
remaining stable before gradually recovering at 2  h 
(Fig. 2). The mean RBF was significantly lower in the con-
trol group (control 120 ± 35 vs. Cytosorb 162 ± 52 mL/
min/100 g; P = 0.022).
Levels of oxygen consumption were significantly 
higher in the Cytosorb group at 1  h (96.4  ±  28.1 vs. 
59.1 ± 17.2 mL/min/g; P = 0.027) and numerically higher 
at 3 h (104.4 ± 31.1 vs. 72.0 ± 8.7 mL/min/g; P = 0.057) 
of perfusion. There was no significant difference in levels 
at 6 h (P = 0.132).
Renal function
There was no significant difference in the total amount 
of urine produced between the groups (control 
1321 ± 497 mL vs. Cytosorb 1462 ± 515 mL; P = 0.644). 
Levels of creatinine clearance were similar between 
groups [area under the curve (AUC) control 31.7 ± 12.3 
vs. Cytosorb 40.5  ±  17.9  mL/min/100  g; P  =  0.109]. 
Table 1 Haemoglobin (Hb), haematocrit (HCT), platelet count, white cell count (WCC) and  heme before  and after  6  h 
of reperfusion
Kidneys were reperfused with autologous blood for 6 h on an ex vivo circuit * P <0.050
Parameters Pre‑perfusion After 6 h of perfusion
Control Cytosorb P value Control Cytosorb P value
Hb (g/L) 45.2 ± 6.5 38.0 ± 5.2 0.115 37.0 ± 9.5 34.6 ± 7.6 0.626
HCT (L/L) 0.16 ± 0.02 0.13 ± 0.01 0.046* 0.14 ± 0.03 0.13 ± 0.02 0.845
Platelets (10 × 9/L) 172 ± 27 106 ± 22 0.008* 106 ± 28 52 ± 26 0.003*
WCC (10 × 9/L) 2.6 ± 0.9 2.4 ± 0.1 0.611 1.7 ± 1.4 1.2 ± 0.7 0.262
Heme (pmol/L) 33.2 ± 1.6 33.1 ± 1.3 0.785 38.8 ± 9.3 67.6 ± 56.1 0.342
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Fig. 2 Mean renal blood flow during 6 h of reperfusion in the control and Cytosorb groups
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Tubular function was also similar between groups (AUC 
fractional excretion of sodium, control 219  ±  60.3 vs. 
Cytosorb 202 ± 93%; P = 0.561).
NGAL
Levels of NGAL in the perfusate were numerically lower 
in the Cytosorb group at 6  h but did not reach statisti-
cal significance (Cytosorb 18 ± 7 vs. control 107 ± 77 ng/
mL; P = 0.055). However, urinary NGAL levels were sig-
nificantly lower in the Cytosorb group throughout reper-
fusion (6 h 1.1 ± 1.7 vs. 173.5 ± 115.5 ng/mL; P = 0.030).
Cytokines
Baseline levels of cytokines (IL-1β, IL-1α, IL-receptor 
antagonist (IL-RA), TNFα, IL-6, IL-8, IL-10 and C-reac-
tive protein (CRP) were similar among groups (P > 0.05). 
There was a numerical increase in the levels of IL-1β, 
IL-1α, IL-RA, TNFα and IL-10 in the control group 
throughout perfusion, whereas levels remained low in the 
Cytosorb group. Levels of IL-6 were significantly lower in 
the Cytosorb group at 3 and 6 h of perfusion (P = 0.040, 
0.023, respectively, Fig.  3). Levels of IL-8 were numeri-
cally lower at 6  h of perfusion in the Cytosorb group 
(P = 0.052). CRP was significantly lower in the Cytosorb 
group at 1, 3 and 6  h perfusion. There was no signifi-
cant difference in levels of IL-1β, IL-1α, IL-RA and IL-10 
between the groups at 1, 3 and 6 h of perfusion (P > 0.05). 
The Cytosorb adsorber reduced IL-1β by 39 ± 54%, IL-1α 
by 48 ±  25%, IL-RA by 52 ±  67%, TNFα by 39 ±  54%, 
IL-6 by 87 ± 12%, IL-8 by 59 ± 54%, IL-10 by 40% and 
CRP by 75 ± 31% after 6 h of perfusion compared to the 
control group.
Prostaglandins
Baseline levels of prostaglandin E2 and prostacyclin were 
similar in both groups (P  =  0.166, 0.236, respectively; 
Fig. 4), whereas baseline levels of thromboxane were sig-
nificantly lower in the Cytosorb group (P = 0.024; Fig. 4). 
There was a numerical decrease in levels of prostaglan-
din E2 in both groups during perfusion (control P = 0.11, 
Cytosorb P = 0.066; Fig. 4a) and levels were significantly 
lower in the Cytosorb group compared to controls at 3 
and 6 h (P =  0.023, 0.001; Fig. 4a). Levels of prostacyc-
lin fell significantly in the Cytosorb group (P  =  0.033; 
Fig. 4b) but there was only a numerical fall in the control 
group (P =  0.095; Fig.  4b). Prostacyclin levels were sig-
nificantly lower in the Cytosorb group at 1, 3 and 6 h of 
perfusion compared to controls (P = 0.008, 0.003, 0.0002; 
Fig.  4b). Levels of thromboxane B2 were significantly 
lower in the Cytosorb group throughout perfusion (1  h 
P = 0.035, 3 h P = 0.025 and 6 h P = 0.005; Fig. 4c).
Gene expression
Paired kidney analysis showed a significant downregula-
tion of renal tissue levels of IL-6 (P = 0.017; Fig. 5) in the 
Cytosorb group relative to the control group after 6 h of 
perfusion. There was also a numerical decrease in renal 
IL-8 expression at 6 h in the Cytosorb group relative to 
the control.
Individual kidney analysis of gene expression at 6 h rel-
ative to baseline showed a statistically significant increase 
in IL-6 (P = 0.017), but there were no differences in IL-8 
(P =  0.176) and IL-1β (P =  0.448) in the control group 
relative to the adsorber.
Discussion
The Cytosorb adsorber has been used widely in the 
clinic with the main indication for the treatment of sep-
sis [21]. Numerous studies have shown that it is a safe 
and effective way of reducing the systemic inflammatory 
response. Suppression of inflammation by inhibiting spe-
cific inflammatory mediators can reduce the effects of IRI 
[22]. Haemoadsorption has the advantage that a range of 
the pro-inflammatory cytokines are effectively reduced 
rather than targeting individual cytokines. This had a 
number of beneficial effects in this isolated kidney model. 
During perfusion there was an increase in the level of cir-
culating pro-inflammatory cytokines, particularly IL-6 
and IL-8 after 3  h, but haemoadsorption significantly 
abrogated this effect. IL-6 and IL-8 are produced as a 
result of NFκB signalling, typically initiated via IL-1β and 
TNFα dependent pathways [23]. There was also a signifi-
cant reduction in IL-6 gene expression and a numerical 
decrease in IL-8, suggesting a sustained effect in altering 
the pro-inflammatory profile. However, longer follow up 
would be needed to determine the full effect of this. Lev-
els of IL-1β and TNFα also increased during reperfusion, 
although to a lesser extent. This may reflect the study of 
an isolated perfused organ as opposed to a whole organ-
ism, where a larger systemic effect might be anticipated. 
Nonetheless, haemoadsorption resulted in a numerical 
reduction in circulating levels.
The Cytosorb adsorber is not specific for pro-inflam-
matory cytokines and as a consequence the anti-inflam-
matory cytokine IL-10 along with the receptor antagonist 
IL-1RA were also reduced by haemoadsorption. IL-10 
is essential for maintaining the integrity and homeosta-
sis of tissue epithelial layers and suppressing the pro-
inflammatory response [24, 25]. Receptor antagonists 
inhibit the binding of their corresponding cytokines to 
prevent their action [26]. IL-1RA can reduce the expres-
sion of intracellular adhesion molecule-1 (ICAM-1), and 
reduce apoptosis [24, 25]. This may explain why we found 
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no difference in the expression of ICAM-1, other pro-
inflammatory cytokines or TLR-4 after 6 h of perfusion. 
Further investigation into the balance of pro- and anti-
inflammatory mediators is necessary.
The results of haemoadsorption in the treatment of 
other inflammatory states such as that induced by car-
diopulmonary bypass has been variable. A randomised 
controlled trial demonstrated no significant differences 
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in pro-inflammatory cytokine levels and no effect on 
patient outcome [16]. One explanation for the lack of 
effect may be the duration of the bypass procedure. 
Patients underwent bypass for a median of 191 min with 
cytokine levels peaking at 2 h after treatment. Our data 
show that the majority of cytokines are upregulated after 
3 h of perfusion. Therefore, the addition of the Cytosorb 
adsorber during cardiopulmonary bypass may be benefi-
cial for more prolonged cases.
In spite of the reduction of pro-inflammatory cytokines 
in this study, haemoadsorption had no effect on renal 
function. All kidneys demonstrated a similar level of glo-
merular and tubular function. NGAL, a reliable marker 
of proximal tubular damage [26, 27], was high in the con-
trol kidneys corresponding to the level of cold ischaemic 
injury. NGAL was reduced in the Cytosorb group, but 
rather than indicating a reduction in injury during reper-
fusion this was probably due to direct haemoadsorption 
of the NGAL molecule, which has a molecular mass of 
23 kDa.
The vascular endothelium plays an important role in 
regulating RBF. In response to ischaemic injury there is 
a reduction in vasodilatory mediators such as prostacy-
clin and prostaglandin E2 and enhanced expression of 
thromboxane, which promotes vasoconstriction, thus 
reducing blood flow [28]. A reduction in the RBF and 
oxygen consumption was evident in the control group 
throughout perfusion and this corresponded with higher 
thromboxane levels. Haemoadsorption improved overall 
blood flow throughout 6 h of reperfusion, but at 30 min 
there was a noticeable rapid decrease in blood flow. This 
may be explained by the finding of lower levels of throm-
boxane and a fall in prostacyclin and prostaglandin E2 in 
the first hour of haemoadsorption. This suggests that the 
beneficial effect of filtering thromboxane was counter-
acted by the filtration of prostacyclin and prostaglandin 
E2.
Platelet activation can enhance IRI and reduce blood 
flow through endothelial adhesion and release of vaso-
constriction mediators [29]. The platelet count was signif-
icantly lower at baseline in the Cytosorb group due to the 
extra volume required to fill the adsorber. This may have 
enhanced the blood flow at the beginning of perfusion. 
Nonetheless, the platelet count fell in both the Cytosorb 
and control groups but the decrement was 10% greater 
after haemoadsorption and this may be another factor in 
improving RBF. Heme is associated with the activation of 
pro-inflammatory, apoptotic and oxidant pathways and 
can result in further organ damage [30] but in this study 
was not significantly reduced by haemoadsorption.
Cytokine filtration has recently been applied to ex vivo 
lung perfusion [31]. Iskender et  al. demonstrated that 
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porcine lungs perfused ex  vivo for 12  h with the Cyto-
sorb adsorber incorporated into the circuit developed 
less oedema, had improved electrolyte balance and lower 
neutrophil infiltration [31]. This present study suggests 
that haemoadsorption could be beneficial to the kid-
ney during ex  vivo perfusion. Ex-vivo normothermic 
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Fig. 5 Gene expression in the Cytosorb group relative to the control group after 6 h reperfusion, normalised to RPL4. The relative fold change for 
each gene between treatment and control was calculated using  2−ΔΔCt. The same analysis was performed comparing the relative expression differ-
ence within each kidney between in situ (baseline) and 6 h. *P < 0.05
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perfusion has recently been introduced into clinical 
practice in kidney transplantation [1]. Adding a Cyto-
sorb adsorber to the system would enable a proportion 
of the inflammatory mediators to be removed. However, 
supplementation particularly of vasodilatory mediators 
would be necessary to maintain a stable environment. 
We chose to examine the effect of adding the adsorber 
into the circuit in the most practical and convenient 
way. Whole blood rather than leucocyte depleted or 
packed red cells was used to determine the full effect of 
the adsorber. This provided important information on 
the preservation conditions, particularly in regard to the 
removal of prostaglandins. A single centrifugal pump cir-
culated the blood based solution at a set pump speed and 
pressure. The Cytosorb was placed in the arterial side of 
the circuit from the membrane oxygenator back into the 
reservoir forming a collateral circulation. The adsorber 
may be more effective if it was placed on the venous arm 
of the system. However, this would require the addition 
of another pump which may alter the perfusion of the 
kidney. The degree of reduction in the levels of cytokines 
was within range of the described effects of the Cytosorb 
and with the low volume in the system it is likely that 
the blood based solution did effectively pass through the 
adsorber.
Conclusion
In an isolated renal perfusion model, haemoadsorption 
reduced the inflammatory response and improved RBF. 
Nonetheless, it had no influence on renal function and 
this may relate to the broad-spectrum action of the Cyto-
sorb adsorber that also removes potentially important 
anti-inflammatory mediators.
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Table 2 qPCR primers
Gene NCBI accession number Primer sequences
ICAM-1 NM_213816.1 TCAATGTGGCCCCTAAACACC
GTCTCTAGGCCAAAGCTGGT
IL-1β NM_214055.1 CCTTGAAACGTGCAATGATGACT
GCCAGCCAGCACTAGAGATT
IL-6 NM_001252429.1 GGGTTCAATCAGGAGACCTGC
CGGCCTCGACATTTCCCTTA
IL-8 NM_213867.1 AGAGTGGACCCCACTGTGAA
TGTTGTTGCTTCTCAGTTCTCTT
HMGB-1 NM_0010040134.1 GCTCAGAAAGGTGGAAGACCAT
TCATAACGGGCCTTGTCCG
RPL4 XM_005659862.2 TGAGCTCTATGGCACTTGGC
GAATCTTCTTGCGTGGTGCG
TLR4 NM_001113039.2 TCATGCTTTCTCCGGGTCAC
TAGGAACCACCTGCACGCAA
Table 3 PCR thermocycler conditions
Segment Temperature (°C) Time (s)
Segment 1
1 cycle
95 600
Segment 2
40 cycles
95 30
59 60
Segment 3
1 cycle
95 60
59 30
95 30
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